Enhanced Tumor Necrosis Factor in Anti-Cd3 Antibody Stimulated Diabetic Nod Mice: Modulation by Pge₁ and Dietary Lipid

References

• Cosimi A B, Burton R C, Colvin R B, Goldstein G, Delmonico F L, LaQuaglia M P, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535–539
   PubMed Web of Science ®Google Scholar
• Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990; 50: 642–648
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran Legendre C. C, et al. Clinical use of OKT-3: The role of cytokine release and xenosensitization. J Autoimm 1988; 1: 631–640
   Web of Science ®Google Scholar
• Ellenhorn J D, Woodle E S, Ghobreal I, Thistlewaite J R, Blue-Stone J A. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990; 50: 608–612
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–608
   PubMed Web of Science ®Google Scholar
• Mackie J, Pankewycz O G, Bastos M B, Kelley V E, Strom T B. Dose related mechanisms of immunosuppression mediated by murine anti-CD3 antibody in pancreatic islets cell transplantation and delayed type hypersensitivity. Transplantation 1990; 49: 1150–1154
   PubMed Web of Science ®Google Scholar
• Pankewycz O, Strom T B, Rubin-Kelley V E. Islet infiltrating T cell clones from non-obese diabetic mice that promote or prevent accelerated onset diabetes. Eur J Immunol, (in press)
   Google Scholar
• Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4 islet-specific T cell clone. Science 1990; 249: 1433–1436
   PubMed Web of Science ®Google Scholar
• Shizuru J A, Taylor-Edwards C, Banks B A, Gregory A K, Fathman C G. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T helper lymphocytes. Science 1988; 240: 659–662
   PubMed Web of Science ®Google Scholar
• Reich E P, Sherwin R S, Kanagawa O, Janeway CA, Jr. An explanation for the protective effects of the MHC Class II I-E molecule in murine diabetes. Nature 1989; 341: 326–328
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Bach J F. In vivo anti-CD3 treatment of autoimmune patients. Lancet 1989; 2: 164
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697–702
   PubMed Web of Science ®Google Scholar
• Kelley V E, Ferretti A, Izui S, Strom T B. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol 1985; 134: 1914–1919
   PubMed Web of Science ®Google Scholar
• Brennan D, Yui M A, Wuthrich R P, Kelley V E. Tumor necrosis factor and IL-1 in New Zealand and Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 3470–3475
   PubMed Web of Science ®Google Scholar
• Endres S, Ghorbani R, Kelley V E, Georgilis K, Lonnemann G, van der Meer J W, et al. The effects of dietary supplementation with ω-3 polyunsaturated fatty acids on the synthesis of IL-1 and TNF by mononuclear cells. NEJM 1989; 320: 265–271
   PubMed Web of Science ®Google Scholar
• Kelley V E, Winkelstein A, Izui S, Dixon F J. Prostoglandin E inhibits T-cell proliferation and renal disease in MRL-lpr mice. Clin Immunol Immunopath 1981; 21: 190–203
   PubMedGoogle Scholar
• Leo O, Foo M, Sachs D H, Samelson L E, Bluestone J A. Identification of a monoclonal antibody specific for a murine T3 poly-peptide. Proc Natl Acad Sci USA 1987; 84: 1374–78
   PubMed Web of Science ®Google Scholar
• Kelley V E, Sneve S, Musinski S. Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 1986; 77: 252–259
   PubMed Web of Science ®Google Scholar
• Burch R M, Knapp D R, Halushka P V. Vasopressin, stimulated thromboxane synthesis in the toad urinary bladder: Effects of imidazole. J Pharmacol Exp Ther 1979; 210: 344–348
   PubMed Web of Science ®Google Scholar
• Meager A, Leung H, Wooley J. Assays for tumor necrosis factor and related cytokines. J Immunol Meth 1989; 116: 1–17
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanatc-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Pennica D, Hayflick J S, Bringman T S, Palladino M A, Goeddel D. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 6060–6064
   PubMed Web of Science ®Google Scholar
• Fransen L, Müller R, Marmenout A, Tavernier J, van der Heyden J, Kawashima E, et al. Molecular cloning of mouse tumor necrosis factor cDNA and its eucaryotic expression. Nud Acids Res 1985; 13: 4417–4429
   PubMed Web of Science ®Google Scholar
• Vlassara H, Brownlee M, Manogue K R, Dinarello C A, Pasagian A. Cachectin/TNF and IL-1 induced glucose-modified proteins: Role in normal tissue remodeling. Science 1988; 240: 1546–1548
   PubMed Web of Science ®Google Scholar
• Campbell I L, Iscaro A, Harrison L C. IFN-γ and tumor necrosis factor-α: Cytotoxicity to murine islets of Langerhans. J Immunol 1988; 141: 2325–2329
   PubMed Web of Science ®Google Scholar
• Prickett J D, Robinson D R, Steinberg A D. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB×NZW F1 mice. J Clin Invest 1981; 68: 56–559
   PubMed Web of Science ®Google Scholar
• Lokesh B R, Sayers T J, Kinsella J E. Interleukin-1 and tumor necrosis factor synthesis by mouse peritoneal macrophages is enhanced by dietary ω-3 polyunsaturated fatty acids. Immunology Letters 1990; 23: 281–286
   PubMed Web of Science ®Google Scholar
• Chouaib S, Bertoglio J H. Prostaglandins E as modulators of the immune response. Lymphokine Research 1988; 7: 237–245
   PubMedGoogle Scholar
• Winkelstein A, Kelley V E. The effects of PGE1 on lymphocytes in NZB/W mice. Clin Immunol Immunopath 1980; 17: 212–218
   PubMedGoogle Scholar
• Spengler R N, Spengler M L, Stieter R M, Remick D G, Larrick J W, Kunkel S L. Modulation of tumor necrosis factor-a gene expression: Desensitization of prostaglandin E2 and cyclic nucleotides. J Immunol 1989; 142: 4346–4350
   PubMed Web of Science ®Google Scholar
• Renz H, Gong J H, Schmidt A, Nain M, Gemsa D. Release of TNF from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol 1988; 141: 2388–2393
   PubMed Web of Science ®Google Scholar
• Bathwich P R, Chensue S W, Larrick J W, Kunkel S L. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Kes Comm 1986; 136: 94–101
   PubMed Web of Science ®Google Scholar
• Moran M, Mozes M F, Maddux M S, Veremis S, Bartkus C, Ketel B, et al. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal transplant recipients treated with cyclosporine and prednisone. NEJM 1990; 322: 1183–1188
   PubMed Web of Science ®Google Scholar
• Michie R H, Manogue K R, Spriggs D R, Revhaug A, O'Dwyer S, Dinarello C A, et al. Detection of circulating tumor necrosis factor after endotoxin administration. NEJM 1988; 318: 1481–1486
   PubMed Web of Science ®Google Scholar
• Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, et al. Recombinant human tumor necrosis factor α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84: 1345–1348
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulson T, Bendtzen K, Dinarello C A, Nerup J. Human tumor necrosis factor potentiates human interleukin-1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 1987; 139: 4077–4082
   PubMed Web of Science ®Google Scholar
• Jacob C O, Also S, Michie S A, McDevitt H O, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990; 87: 968–972
   PubMed Web of Science ®Google Scholar